DCF Advisers’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-1,300
| Closed | -$249K | – | 73 |
|
|
2023
Q4 | $249K | Sell |
1,300
-500
| -28% | -$95.7K | 0.14% | 60 |
|
|
2023
Q3 | $319K | Buy |
1,800
+200
| +13% | +$35.4K | 0.17% | 57 |
|
|
2023
Q2 | $304K | Buy |
1,600
+200
| +14% | +$38K | 0.16% | 64 |
|
|
2023
Q1 | $280K | Hold |
1,400
| – | – | 0.17% | 52 |
|
|
2022
Q4 | $333K | Hold |
1,400
| – | – | 0.22% | 48 |
|
|
2022
Q3 | $280K | Sell |
1,400
-3,600
| -72% | -$720K | 0.18% | 53 |
|
|
2022
Q2 | $729K | Sell |
5,000
-14,000
| -74% | -$2.04M | 0.43% | 40 |
|
|
2022
Q1 | $3.1M | Buy |
19,000
+1,000
| +6% | +$163K | 1.36% | 18 |
|
|
2021
Q4 | $3.05M | Buy |
18,000
+500
| +3% | +$84.8K | 1.24% | 21 |
|
|
2021
Q3 | $3.3M | Hold |
17,500
| – | – | 1.46% | 20 |
|
|
2021
Q2 | $2.97M | Sell |
17,500
-2,500
| -13% | -$424K | 1.05% | 21 |
|
|
2021
Q1 | $2.82M | Hold |
20,000
| – | – | 1.23% | 20 |
|
|
2020
Q4 | $2.6M | Sell |
20,000
-7,500
| -27% | -$975K | 1.07% | 22 |
|
|
2020
Q3 | $4M | Hold |
27,500
| – | – | 2.05% | 14 |
|
|
2020
Q2 | $4.07M | Sell |
27,500
-1,500
| -5% | -$222K | 2.28% | 11 |
|
|
2020
Q1 | $3.16M | Sell |
29,000
-11,000
| -28% | -$1.2M | 2.07% | 15 |
|
|
2019
Q4 | $4.61M | Buy |
+40,000
| New | +$4.61M | 2.92% | 10 |
|